MAPT genotype-dependent mitochondrial aberration and ROS production trigger dysfunction and death in cortical neurons of patients with hereditary FTLD.


Journal

Redox biology
ISSN: 2213-2317
Titre abrégé: Redox Biol
Pays: Netherlands
ID NLM: 101605639

Informations de publication

Date de publication:
02 2023
Historique:
received: 21 12 2022
accepted: 28 12 2022
pubmed: 5 1 2023
medline: 18 1 2023
entrez: 4 1 2023
Statut: ppublish

Résumé

Tauopathies are a major type of proteinopathies underlying neurodegenerative diseases. Mutations in the tau-encoding MAPT-gene lead to hereditary cases of frontotemporal lobar degeneration (FTLD)-tau, which span a wide phenotypic and pathological spectrum. Some of these mutations, such as the N279K mutation, result in a shift of the physiological 3R/4R ratio towards the more aggregation prone 4R isoform. Other mutations such as V337M cause a decrease in the in vitro affinity of tau to microtubules and a reduced ability to promote microtubule assembly. Whether both mutations address similar downstream signalling cascades remains unclear but is important for potential rescue strategies. Here, we developed a novel and optimised forward programming protocol for the rapid and highly efficient production of pure cultures of glutamatergic cortical neurons from hiPSCs. We apply this protocol to delineate mechanisms of neurodegeneration in an FTLD-tau hiPSC-model consisting of MAPT

Identifiants

pubmed: 36599286
pii: S2213-2317(22)00369-X
doi: 10.1016/j.redox.2022.102597
pmc: PMC9817175
pii:
doi:

Substances chimiques

Reactive Oxygen Species 0
tau Proteins 0
Protein Isoforms 0
MAPT protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102597

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest LK: none; AS: A patent application for the optimised forward programming protocol has been filed and submitted. CBS: none. LG: none. TK: none. AE: none. PD: none. MN: none. GS: none. SGM: none. HRS: none. HW: none. SK: none. MP: A patent application for the optimised forward programming protocol has been filed and submitted.

Auteurs

Lisanne Korn (L)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Anna M Speicher (AM)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Christina B Schroeter (CB)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Lukas Gola (L)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Thilo Kaehne (T)

Institute of Experimental Internal Medicine, Otto-von-Guericke University, Magdeburg, Germany.

Alexander Engler (A)

Institute of Experimental Internal Medicine, Otto-von-Guericke University, Magdeburg, Germany.

Paul Disse (P)

Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany; Chemical Biology of Ion Channels (Chembion), GRK 2515, University of Münster, 48149, Münster, Germany.

Juncal Fernández-Orth (J)

Department of Pediatric Hematology and Oncology, University Medical Center Freiburg, Germany.

Júlia Csatári (J)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Michael Naumann (M)

Institute of Experimental Internal Medicine, Otto-von-Guericke University, Magdeburg, Germany.

Guiscard Seebohm (G)

Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany; Chemical Biology of Ion Channels (Chembion), GRK 2515, University of Münster, 48149, Münster, Germany.

Sven G Meuth (SG)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Hans R Schöler (HR)

Department of Cell and Developmental Biology, Max-Planck-Institute for Molecular Biomedicine, Münster, Germany; Medical Faculty, University of Münster, Münster, Germany.

Heinz Wiendl (H)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Stjepana Kovac (S)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Matthias Pawlowski (M)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. Electronic address: matthias.pawlowski@ukmuenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH